Sattva Swarup Neelapu MD

Hematologic Oncology

Physician

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161

Dr. Neelapu is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Neelapu's full profile Already have an account?

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
NYC Health & Hospitals/South Brooklyn HealthResidency, Internal Medicine, 1992 - 1995
Jawaharlal Institute of Postgraduate Medical Education and ResearchClass of 1992

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 1995 - Present
TX State Medical License 2005 - 2028
OK State Medical License 2020 - 2021
MD State Medical License 1998 - 2005
UT State Medical License 1995 - 1996
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015

Clinical Trials

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma
COMPLETED
PHASE1
Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
COMPLETED
PHASE2
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
COMPLETED
PHASE1

Publications & Presentations

PubMed

ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy.
Miguel-Angel Perales, Jorg Dietrich, Juliane Gust, Bianca Santomasso, Kai Rejeski
Transplantation and Cellular Therapy. 2026-10-01
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
Andrew P Jallouk, Zhongqi Ge, Vivek Kaimal, Kristen Zhang, Elvin J Lauron
Cancer Discovery. 2026-09-25
Plain language summary of the ZUMA-5 study of axicabtagene ciloleucel for people with relapsed or refractory slow-growing non-Hodgkin lymphoma.
Sattva S Neelapu, Olga Nikolajeva, Caron A Jacobson
Future Oncology. 2026-09-16

Journal Articles

Assessment of Radiation Doses Delivered to Organs at Risk Among Patients with Early-Stage Favorable Hodgkin Lymphoma Treated with Contemporary Radiation Therapy
Chelsea C Pinnix, Jillian R Gunther, Sarah A Milgrom, Jason Westin, Simrit Parmar, Loretta Nastoupil, Sattva Neelapu, Bouthaina S Dabaja, JAMA Network Open
Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin Lymphoma
Peter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
Management Guidelines for Paediatric Patients Receiving Chimeric Antigen Receptor T Cell Therapy
Kris M Mahadeo, Julie C Fitzgerald, Marie E Steiner, Partow Kebriaei, Katayoun Rezvani, Ira M Cheifetz, John M Slopis, Paul L Martin, Sattva S Neelapu, Agne Tarasevici..., Nature

Abstracts/Posters

Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Sattva S Neelapu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
Sattva S Neelapu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor P...
Sattva S Neelapu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Hit the Ground Running: What You Need to Know About CAR T-Cell Therapy
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

ZUMA-5: Curative Potential of Axi-Cel in Follicular LymphomaJanuary 3rd, 2025
$Kite’s Yescarta® Only CAR T-cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024$
Kite’s Yescarta® Only CAR T-cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024December 9th, 2024
MD Anderson Research Highlights: ASH 2024 Special EditionDecember 4th, 2024

Grant Support

[18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse EventsUNIVERSITY OF TX MD ANDERSON CAN CTR2022–2027
Predictors Of Clinical Outcome After Therapeutic Vaccination In Follicular LymphoNational Cancer Institute2011–2012
Enhancing Antitumor Immunity With Anti-Pd-1 Antibody In Follicular Lymphoma.National Cancer Institute2010–2011
Antigen Discovery And Development Of Tumor-Specific Lymphoma ImmunotherapyNational Cancer Institute2007–2010